| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 15
| Issue : 4 | Page : 161-170 |
|
|
Outcome of patients with severe COVID-19 pneumonia treated with high-dose corticosteroid pulse therapy: A retrospective study
Hanife Nur Karakoc1, Aysun Aksoy2, Merve Aydin3, Safiye Nur Ozcan1, Gulcin Zengin4, Hacer Aksit Yasar5
1 Department of Infectious Diseases and Clinical Microbiology, Bitlis Tatvan Public Hospital, Bitlis, Turkey
2 Department of Romatology, Bitlis Tatvan Public Hospital, Bitlis, Turkey
3 Department of Medical Microbiology, KTO Karatay University Faculty of Medicine, Konya, Turkey
4 Department of Radiology, Bitlis Tatvan Public Hospital, Bitlis, Turkey
5 Department of Pulmonary Diseases, Bitlis Tatvan Public Hospital, Bitlis, Turkey
Correspondence Address:
Hanife Nur Karakoc
Department of Infectious Diseases and Clinical Microbiology, Bitlis Tatvan Public Hospital, Bitlis
Turkey
 Source of Support: The authors received no extramural funding for the study, Conflict of Interest: None
DOI: 10.4103/1995-7645.343881
|
|
|
Objective: To assess the effectiveness of high-dose corticosteroid pulse therapy and evaluate possible factors associated with 28-day mortality in hospitalised patients with severe COVID-19 pneumonia.
Methods: We conducted a single-centre retrospective cohort study on hospitalised patients with clinical, epidemiological, and/or radiologically confirmed and suspected COVID-19 at Bitlis Tatvan State Hospital in Turkey between December 1, 2020 and June 1, 2021. All data of the study participants were recorded, and all patients received intravenous high-dose corticosteroid pulse therapy. The Ordinal Scale for Clinical Improvement (OSCI), Charlson Comorbidity Index and Total Severity Score were calculated. Univariate and multivariate Cox regression models were performed to evaluate the clinical and laboratory parameters that may affect the 28-day mortality.
Results: A total of 126 patients were included in the analysis. The 28-day mortality rate of the patients was 22.2%. Laboratory and clinical improvement were observed in 77.8% (98/126) of patients after high-dose corticosteroid pulse therapy. There was a statistically significant difference between the survivors and non-survivors in terms of age, platelet count, neutrophil/lymphocyte ratio, and OSCI, Charlson Comorbidity Index, and Total Severity Score (P<0.001). Multivariate Cox regression analysis revealed that age [HR 1.047 (95% CI 1.01-1.08)], use of prophylactic anticoagulation [HR 0.838 (95% CI 0.79-0.89)], and bacterial co-infection [HR 3.966 (95% CI 1.40-11.21)] were significant determinants of mortality. Early C-reactive protein (CRP) response, decreased oxygen requirement, and improving respiratory rate/OSCI scores after administration of high-dose corticosteroid pulse therapy could contribute to clinical improvement.
Conclusions: CRP response, needed oxygen and OSCI scores can be used as prognostic factors to select patients who will benefit from high-dose corticosteroid pulse therapy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
